Direct oral anticoagulant: Review article
Venous thromboembolism (VTE) and atrial fibrillation (AF) is a major burden on the health care system. The average occurrence of venous thromboembolism annually is around 108 per 100,000 person-year. DOACs have transformed treatment of coagulation disorder, and now, it is the leading treatment for s...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Journal of Family Medicine and Primary Care |
| Subjects: | |
| Online Access: | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=8;spage=4180;epage=4183;aulast=Nasiri |
| _version_ | 1828725386984292352 |
|---|---|
| author | Abdulrahman Nasiri Ahmed AlQahtani Nora H Rayes Rawan AlQahtani Reem Alkharras Hamad Alghethber |
| author_facet | Abdulrahman Nasiri Ahmed AlQahtani Nora H Rayes Rawan AlQahtani Reem Alkharras Hamad Alghethber |
| author_sort | Abdulrahman Nasiri |
| collection | DOAJ |
| description | Venous thromboembolism (VTE) and atrial fibrillation (AF) is a major burden on the health care system. The average occurrence of venous thromboembolism annually is around 108 per 100,000 person-year. DOACs have transformed treatment of coagulation disorder, and now, it is the leading treatment for stroke prevention in AF and VTE prophylaxis and treatment. For more many years, oral vitamin K antagonists (VKAs) were the drug of choice in managing VTE. VKAs treatment is safe and effective if therapeutic international normalized ratio (INR) maintained on the target. However, achieving a stable, therapeutic international normalized ratio (INR) can be difficult and challenging in the context of drug and food interactions and liver disorder, resulting in undertreatment which increases the risk of thromboembolism or overtreatment which might cause bleeding. Herein, we provide an overview of DOACs indications, use in specific comorbidities, monitoring parameters, perioperative management, and reversal agents. |
| first_indexed | 2024-04-12T13:26:31Z |
| format | Article |
| id | doaj.art-9fd761bef770472e90e773b6035f1ef7 |
| institution | Directory Open Access Journal |
| issn | 2249-4863 |
| language | English |
| last_indexed | 2024-04-12T13:26:31Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Family Medicine and Primary Care |
| spelling | doaj.art-9fd761bef770472e90e773b6035f1ef72022-12-22T03:31:19ZengWolters Kluwer Medknow PublicationsJournal of Family Medicine and Primary Care2249-48632022-01-011184180418310.4103/jfmpc.jfmpc_2253_21Direct oral anticoagulant: Review articleAbdulrahman NasiriAhmed AlQahtaniNora H RayesRawan AlQahtaniReem AlkharrasHamad AlghethberVenous thromboembolism (VTE) and atrial fibrillation (AF) is a major burden on the health care system. The average occurrence of venous thromboembolism annually is around 108 per 100,000 person-year. DOACs have transformed treatment of coagulation disorder, and now, it is the leading treatment for stroke prevention in AF and VTE prophylaxis and treatment. For more many years, oral vitamin K antagonists (VKAs) were the drug of choice in managing VTE. VKAs treatment is safe and effective if therapeutic international normalized ratio (INR) maintained on the target. However, achieving a stable, therapeutic international normalized ratio (INR) can be difficult and challenging in the context of drug and food interactions and liver disorder, resulting in undertreatment which increases the risk of thromboembolism or overtreatment which might cause bleeding. Herein, we provide an overview of DOACs indications, use in specific comorbidities, monitoring parameters, perioperative management, and reversal agents.http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=8;spage=4180;epage=4183;aulast=Nasirianticoagulantdoacseffectivefactor xaoverviewrivaroxaban |
| spellingShingle | Abdulrahman Nasiri Ahmed AlQahtani Nora H Rayes Rawan AlQahtani Reem Alkharras Hamad Alghethber Direct oral anticoagulant: Review article Journal of Family Medicine and Primary Care anticoagulant doacs effective factor xa overview rivaroxaban |
| title | Direct oral anticoagulant: Review article |
| title_full | Direct oral anticoagulant: Review article |
| title_fullStr | Direct oral anticoagulant: Review article |
| title_full_unstemmed | Direct oral anticoagulant: Review article |
| title_short | Direct oral anticoagulant: Review article |
| title_sort | direct oral anticoagulant review article |
| topic | anticoagulant doacs effective factor xa overview rivaroxaban |
| url | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=8;spage=4180;epage=4183;aulast=Nasiri |
| work_keys_str_mv | AT abdulrahmannasiri directoralanticoagulantreviewarticle AT ahmedalqahtani directoralanticoagulantreviewarticle AT norahrayes directoralanticoagulantreviewarticle AT rawanalqahtani directoralanticoagulantreviewarticle AT reemalkharras directoralanticoagulantreviewarticle AT hamadalghethber directoralanticoagulantreviewarticle |